Zealand Pharma A/S (OTCMKTS:ZLDPF) Reaches New 52-Week Low - Should You Sell?

Shares of Zealand Pharma A/S (OTCMKTS:ZLDPF - Get Free Report) reached a new 52-week low on Tuesday . The stock traded as low as $57.04 and last traded at $57.04, with a volume of 445 shares changing hands. The stock had previously closed at $57.28.

Wall Street Analysts Forecast Growth

Separately, William Blair raised Zealand Pharma A/S from a "hold" rating to a "strong-buy" rating in a report on Friday, March 7th.

Zealand Pharma A/S Stock Down 2.6%

The business's 50 day moving average price is $66.23 and its 200-day moving average price is $83.42. The company has a debt-to-equity ratio of 0.03, a current ratio of 25.10 and a quick ratio of 25.07. The company has a market cap of $3.96 billion, a P/E ratio of -22.41 and a beta of 0.74.

Zealand Pharma A/S (OTCMKTS:ZLDPF - Get Free Report) last announced its earnings results on Thursday, May 8th. The company reported ($0.67) earnings per share for the quarter, beating analysts' consensus estimates of ($0.77) by $0.10. The company had revenue of $1.14 million during the quarter, compared to analyst estimates of $248.61 million. Zealand Pharma A/S had a negative return on equity of 13.40% and a negative net margin of 2,127.09%. On average, analysts anticipate that Zealand Pharma A/S will post -2.19 earnings per share for the current fiscal year.

About Zealand Pharma A/S

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.